Pharmaceutical executives seemed to reach a consensus that it'll take government action to solve the conundrum of how we get to lower drug prices.
\n\nPharmaceutical CEOs and executives from seven companies went in front of Congress on Tuesday to testify about the high price of prescription drugs.\nOver the course of a few hours, senators grilled the executives about the role they play in setting high prices for Americans as well as what they could do to fix it. \nToward the end, the executives seemed to reach a consensus that it;'ll take government action to solve the conundrum of how we get to lower prices.
\n;"We couldn’t do that independently of major reform because we would lose formulary placement if we were doing that in isolation, especially in competitive areas,;" Brandicourt said. \nAstraZeneca CEO Pascal Soriot said the US healthcare system is set up in a way that no longer works. \n;"We are in a system that used to be fit for purpose and drove enormous savings, but is no longer fit for purpose,;" Soriot said.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Aurora Cannabis to acquire 51% stake in Portugal's Gaia Pharma, set up medical cannabis facility
Baca lebih lajut »
These Senators Received The Biggest Checks From Pharma Companies Testifying TuesdaySeven pharma executives are expected to face tough questions about the price of their drugs Tuesday before the U.S. Senate Finance Committee. They’ll also be answering to a group that’s received hundreds of thousands of dollars in campaign contributions from their own companies’ PACs.
Baca lebih lajut »
Pharma giants are betting billions on gene therapies that could fundamentally change how we treat diseasesRecent deals like Roche's $4.8 billion bet on Spark and Novartis' $8.7 billion acquisition of AveXis show that big pharma is betting big on gene therapy.
Baca lebih lajut »
GE-Danaher pharma deal is a win-win remedyCEO Larry Culp is unloading the conglomerate’s biologics unit to his old employer for $21 bln. It’s his boldest downsizing move yet and will help cut leverage. Danaher gains scale in its health business at a reasonable price while Culp needed a sale, not necessarily top dollar.
Baca lebih lajut »
‘It’s finally pharma’s turn’: Drug CEOs face Capitol Hill reckoningSeven drugmakers will be grilled over high prices at a hearing this week, in what could be a watershed moment for the industry.
Baca lebih lajut »
Pharma giant Roche just bought biotech firm Spark, the maker of an $850,000 eye drugRoche is set to buy gene therapy firm Spark Therapeutics for about $4.8 billion. Spark's stock more than doubled in premarket trading.
Baca lebih lajut »
Grassley to Big Pharma: 'I'm sick and tired of the blame game'Sen. Chuck Grassley opened a hearing into the rising costs of prescription medicine on Tuesday by blasting Big Pharma, saying that skyrocketing prices are hurting Americans and that the time has come for a reckoning. 'I'm sick and tired of the blame game.'
Baca lebih lajut »
Big Pharma companies defending skyrocketing prices on the HillAmericans spent more than $300 billion on prescription drugs last year alone and that’s set to get even higher. Right now, the heads of seven major pharmaceutical companies are on Capitol Hill, trying to defend the skyrocketing costs. Ali Velshi and Stephanie Ruhle are joined by Hippo’s Chief Patient Advocate, MJ Hegar, who claims to have the answer to all of this.
Baca lebih lajut »